Nursing Pharmacology:  Antiviral Drugs

• Antiretroviral Drugs Used in Treating HIV Infection

  • →Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (continued):

    • Abacavir (Ziagen)

      • Abacavir (Ziagen) is an antiretroviral that is classified as a guanosine analogue.¹ 

        • Abacavir is another example of a prodrug, given that it must be phosphorylated to a triphosphate derivative for pharmacological activity.

      • Mutations and Resistance to Abacavir:

        • Specific mutations in the reverse transcriptase gene can result in resistance to abacavir anti-retroviral activity.¹ 

        • There are four major mutational sites of interest.⁸

        • These mutations by themselves may be associated with limited abacavir resistance (2-4-fold).¹ 

          • In combination these substitutions may reduce abacavir susceptibility by up to 10 times, however.

      • Pharmacokinetics:

        • Abacavir is about 80% absorbed following oral administration and the drug's absorption is unaffected by food.⁷

          • Drug half-life is about 1.5 hours. 

          • Abacavir undergoes hepatic metabolism using Phase II systems, supporting glucuronidation and carboxylation.

            • The liver microsomal P450 drug metabolizing system does not participate in abacavir metabolism and abacavir does not act as an inhibitor of CYPP450 isoforms.

          • With respect to CNS penetration, about one-third of the plasma levels are found in the cerebrospinal fluid.⁷

          • Abacavir exhibits about 50% plasma protein binding.¹

      • Adverse Effects:

        • "Pharmacogenetics of Abacavir and Cabamazepine Hypersensitivity"¹⁰

          Attribution:  Larriva M Pharmacogenetics of Abacavir and Carbamazepine Hypersensitivity. https://www.youtube.com/watch?v=UAbieuea3yA (12/2012) HIV/AIDS (CDC) YouTube Channel:  https://www.cdc.gov/hiv/basics/whatishiv.html

         

        • An important adverse effect associated with abacavir administration is a specific, possibly fatal hypersensitivity reaction.

          • Serious Abacavir Adverse Reaction¹

            Presenting symptoms of this reaction is fever, abdominal pain as well as G.I. complaints.1  Furthermore, a "mild maculopapular rash" along with malaise or fatigue may also present. Symptoms occur about 11 days following abacavir were treatment initiation in almost all cases, (93%), occur within a month and a half of beginning the back of your treatment. Should concurrent fever with abdominal pain and rash begin within six weeks present following abacavir, immediate drug discontinuation is required, since these symptoms are diagnostic for abacavir hypersensitivity syndrome.1  Continuing treatment results in a worsening of the condition. Furthermore, abacavir should never be restarted once discontinued for hypersensitivity, since a second exposure to the drug causes severe symptoms recurrence, worsened by hypotension, shock or even death.  Restarting abacavir in this circumstance represents a permanent contraindication. An estimation of mortality rate following restarting abacavir in those individual shown sensitive is about 4%.1,11 "Frequency of symptoms associated with hypersensitivity to abacavir"11 "Symptoms occurring in >10% of patients either on initial presentation or on rechallenge after temporary discontinuation are shown"11 (attribution:  figure above corresponds to Feb. 5, reference 11) Hetherington R Steel H Naderer O et al.  Hypersensitivity reactions during therapy with abacavir:  analysis of 636 cases for clinical presentation and risk factors [abstract and post 60] 7th Conference on Retroviruses and Opportunistic Infections: 2000 Jan 30- Feb. 2; San Francisco

      • Therapeutics:

        • Abacavir (Ziagen) is effective in treating HIV-1 infection especially when administered in combination with other antiretroviral drugs.¹ 

          • Initially, abacavir used as monotherapy reduced the HIV-load marker, HIV plasma RNA levels, by as much as 300 times more than that seen with other antiretroviral nucleosides.¹ 

            • At the same time abacavir administration increased CD4+ T cell lymphocyte counts by 80-200 cells/cc.

          • Abacavir is typically administered in combination with other nucleoside analogues, non-nucleoside reverse transcriptase inhibitors (nnRTIs) and protease inhibitors.¹ 

            • The addition of abacavir to zidovudine and lamivudine further decreases plasma HIV-1 RNA compared to that observed with zidovudine plus lamivudine alone.

            • Coformulated with zidovudine and lamivudine, abacavir (Trizivir) is available for twice-daily administration.

              • Even more effective than this combination appears to be another three drug combination, zidovudine, lamivudine and efavirenz or four drug combination including zidovudine, lamivudine, abacavir and efavirenz.¹  

          • The most common method of abacavir administration is as a coformulation with lamivudine (Epzicom).¹

          • Some clinical studies suggest that abacavir + lamivudine is the preferred "backbone" combination; whereas, other studies suggest this combination as an alternative nucleoside backbone.⁶

            • In comparing tenofovir + emtricitabine with abacavir + lamivudine (in combination with efavirenz or ritonavir-boosted atazanavir) noted decreased serologic responses in patients with viral loads greater than 100,000 and RNA copies/cc, if they were randomized to receive the abacavir + lamivudine combination.

            • For those individuals exhibiting a baseline viral load of <100,000 copies/cc, comparable times to virologic failure for abacavir + lamivudine or for tenofovir + emtricitabine were reported.⁶

          •  

            Abacavir (Ziagen) Formulation Example

   

   

References

Flexner C Antiretroviral Agents and Treatment of HIV Infection, Chapter 59  in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011. Fauci AS Lane HC Chapter 226, Human Immunodeficiency Virus Disease:  AIDS and Related Disorders, in Harrison's Online   (Kasper DL Fauci AS Hauser SL Longo DL Jameson JL Loscalzo J, Eds.),  Harrison's Principles of Internal Medicine, 19th edition, The McGraw-Hill Companies, Inc. 2015 (on-line edition) Longo DL Fauci AS  188, The Human Retroviruses, in Harrison's Online   (Dan L. Longo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 18th edition, The McGraw-Hill Companies, Inc. 2012. Woster PM Chapter 43:  Antiviral Agents and Protease Inhibitors in Foye's Principles of Medicinal Chemistry 6e, Lemke, TL Williams DA, eds; Roche VG Zito SW, asst eds) Wolters Kluwer|Lippincott Williams & Wilkins 1214, 2008. HIV Overview:  The HIV Life Cycle, Education Materials, AIDSinfo, NIH http://aidsinfo.nih.gov/education-materials/fact-sheets/19/73/the-hiv-life-cycle Tsibris AMN Hirsch MS Chapter 130 Antiretroviral Therapy for Human Immunodeficiency Virus Infection in Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8e (Bennett JE Bolin R Blaser, eds) Elsevier, Inc/Saunders 2015, online version. Safrin S Chapter 49:  Antiviral Agents:  Antiretroviral Agents in Basic & Clinical Pharmacology 13e (Katzung BG Trevor AJ, eds) 2015, online edition. Wensing AM Calvez V Gunthard JF Johnson VA Paredes R Pillay D Shafer RW Richman DD Special Contribution:  2014 Update of the Drug Resistance Multations in HIV-1 Topics in Antivral Medicine 22(3)  June/July 2014, https://www.iasusa.org/sites/default/files/tam/22-3-642.pdf Gallant JE Gerondelis PZ Wainberg MA Shulman NS Haubrich RH St Clain M Lanier ER Hellmann NS Richman DD Nucleoside and nucleotide analogue reverse transcriptase inhibitors:  a clinical review of antiretroviral resistance.  Antiviral Therapy 8:  489-506. http://www.intmedpress.com/journals/avt/abstract.cfm?id=1027&pid=88; http://www.ncbi.nlm.nih.gov/pubmed/14760883. (second sourced from reference 1 above) Larriva M Pharmacogenetics of Abacavir and Carbamazepine Hypersensitivity. https://www.youtube.com/watch?v=UAbieuea3yA Hervey PS Perry CM Abacavir:  A Review of its Clinical Potential In Patients with HIV Infection. Drugs 60(2)  447-479 August, 2000. http://www.ncbi.nlm.nih.gov/pubmed/10983741 (second sourced from reference 1).

 

Disclaimer

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.